Clinical trial
Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
NCT00841828
Study timeline
Study start (actual)2009-02-01Date precision: month
Registry last updated2023-03-31
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
Interventions
EpirubicinDRUG · verified · RxNorm: epirubicin
CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide
DocetaxelDRUG · verified · RxNorm: docetaxel
LapatinibDRUG · verified · RxNorm: lapatinib
TrastuzumabDRUG · verified · RxNorm: trastuzumab
Sponsors & collaborators
Spanish Breast Cancer Research Grouplead sponsor
GlaxoSmithKlinecollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00841828 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.